Market Overview:
The global sustained release injectables market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of sustained release injectables. Based on type, the global sustained release injectables market is segmented into naltrexone, exenatide, estradiol, and other types. The naltrexone segment is expected to account for the largest share of the global market in 2018 owing to its high usage rates for treating opioid addiction and alcohol dependence disorders. Based on application, the diabetes segment is expected to account for the largest share of the global market in 2018 owing to its high prevalence across all regions worldwide.
Product Definition:
Sustained release injectables are a class of medications that are designed to release the medication slowly over time. This is important because it helps to ensure that the medication is absorbed evenly and avoids large spikes in blood levels which can be dangerous.
Naltrexone:
Naltrexone, also known as Revlimid, is an opioid antagonist. It works by blocking the receptors that are involved in the body's response to opioids. The drug was approved by the U.S Food and Drug Administration (FDA) for use with opioid addiction in 1994 and 1995 respectively.
Exenatide:
Exenatide is a new peptide-based drug that is developed by Novartis AG. It works by increasing the excretion of sodium in the urine, which reduces the volume of extracellular fluid in patients with hypertension. Exenatide was approved by FDA for treatment of hypertension on March 31, 2017 and was labeled as a breakthrough therapy under USPTO law.
Application Insights:
The diabetes segment dominated the global market in 2017 and is expected to continue its dominance over the forecast period. The growing prevalence of diabetes, which currently affects around 463 million people globally, is anticipated to boost product demand in the coming years.
In addition, sustained release injectables are used for treating type 1 and type 2 diabetes as well as for preventing diabetic complications such as ketoacidosis and blindness. Furthermore, exogenous insulin delivery has a significant impact on reducing HbA1c levels along with improving patient compliance by decreasing injection frequency. These factors are likely to increase product penetration for treating diabetes during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing cases of chronic diseases, rising awareness about advanced therapeutics, and availability of a well-developed healthcare infrastructure. Moreover, presence of key players such as Pfizer Inc.; Merck & Co., Inc.; and Johnson & Johnson Services India Pvt. Ltd.
Asia Pacific is anticipated to witness lucrative growth over the next eight years owing to factors such as improving healthcare facilities due to increased funding by governments and private organizations; growing investment by pharmaceutical companies for manufacturing SRT injectables; increase in diabetes patients due mainly expansion in population aged 65 years or more which increases susceptibility towards diabetic complications like kidney failure requiring sustained release injectables; rise in awareness about these products among physicians & patients resulting into higher adoption rates for these therapies across countries like China, Japan, South Korea etc.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. The rise in the number of chronic diseases is expected to drive the demand for sustained release injectables in the coming years.
- Technological advancements: The sustained release injectables market is witnessing rapid technological advancements, with new products being launched regularly. This has led to an increase in their adoption by healthcare professionals and patients alike. Such technological advances are likely to fuel the growth of this market in the coming years.
- Growing awareness about benefits offered by sustained release injectables: There is a growing awareness among patients and healthcare professionals about the benefits offered by sustained release injectables over traditional injections or oral medications. This is likely to boost demand for these products in the coming years, thereby fuelling market growth..
Scope Of The Report
Report Attributes
Report Details
Report Title
Sustained Release Injectables Market Research Report
By Type
Naltrexone, Exenatide, Estradiol, Other
By Application
Diabetes, Leukemia, Acromegaly, Other
By Companies
AstraZeneca, Eli Lilly, Sanofi, Roche, Novartis, Aurobindo, Avadel, Biomarin, Camurus, Critical Pharmaceuticals, Alkermes, Amylin, Ascendis Pharma, Taiwan Liposome Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Sustained Release Injectables Market Report Segments:
The global Sustained Release Injectables market is segmented on the basis of:
Types
Naltrexone, Exenatide, Estradiol, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diabetes, Leukemia, Acromegaly, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Eli Lilly
- Sanofi
- Roche
- Novartis
- Aurobindo
- Avadel
- Biomarin
- Camurus
- Critical Pharmaceuticals
- Alkermes
- Amylin
- Ascendis Pharma
- Taiwan Liposome Company
Highlights of The Sustained Release Injectables Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Naltrexone
- Exenatide
- Estradiol
- Other
- By Application:
- Diabetes
- Leukemia
- Acromegaly
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sustained Release Injectables Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sustained release injectables are a type of medication that are released over an extended period of time. This means that the medication is released slowly into the body, which can help to avoid side effects.
Some of the key players operating in the sustained release injectables market are AstraZeneca, Eli Lilly, Sanofi, Roche, Novartis, Aurobindo, Avadel, Biomarin, Camurus, Critical Pharmaceuticals, Alkermes, Amylin, Ascendis Pharma, Taiwan Liposome Company.
The sustained release injectables market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sustained Release Injectables Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sustained Release Injectables Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sustained Release Injectables Market - Supply Chain
4.5. Global Sustained Release Injectables Market Forecast
4.5.1. Sustained Release Injectables Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sustained Release Injectables Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sustained Release Injectables Market Absolute $ Opportunity
5. Global Sustained Release Injectables Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sustained Release Injectables Market Size and Volume Forecast by Type
5.3.1. Naltrexone
5.3.2. Exenatide
5.3.3. Estradiol
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sustained Release Injectables Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sustained Release Injectables Market Size and Volume Forecast by Application
6.3.1. Diabetes
6.3.2. Leukemia
6.3.3. Acromegaly
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sustained Release Injectables Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sustained Release Injectables Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sustained Release Injectables Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sustained Release Injectables Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sustained Release Injectables Demand Share Forecast, 2019-2026
9. North America Sustained Release Injectables Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sustained Release Injectables Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sustained Release Injectables Market Size and Volume Forecast by Application
9.4.1. Diabetes
9.4.2. Leukemia
9.4.3. Acromegaly
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sustained Release Injectables Market Size and Volume Forecast by Type
9.7.1. Naltrexone
9.7.2. Exenatide
9.7.3. Estradiol
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sustained Release Injectables Demand Share Forecast, 2019-2026
10. Latin America Sustained Release Injectables Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sustained Release Injectables Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sustained Release Injectables Market Size and Volume Forecast by Application
10.4.1. Diabetes
10.4.2. Leukemia
10.4.3. Acromegaly
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sustained Release Injectables Market Size and Volume Forecast by Type
10.7.1. Naltrexone
10.7.2. Exenatide
10.7.3. Estradiol
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sustained Release Injectables Demand Share Forecast, 2019-2026
11. Europe Sustained Release Injectables Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sustained Release Injectables Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sustained Release Injectables Market Size and Volume Forecast by Application
11.4.1. Diabetes
11.4.2. Leukemia
11.4.3. Acromegaly
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sustained Release Injectables Market Size and Volume Forecast by Type
11.7.1. Naltrexone
11.7.2. Exenatide
11.7.3. Estradiol
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sustained Release Injectables Demand Share, 2019-2026
12. Asia Pacific Sustained Release Injectables Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sustained Release Injectables Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sustained Release Injectables Market Size and Volume Forecast by Application
12.4.1. Diabetes
12.4.2. Leukemia
12.4.3. Acromegaly
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sustained Release Injectables Market Size and Volume Forecast by Type
12.7.1. Naltrexone
12.7.2. Exenatide
12.7.3. Estradiol
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sustained Release Injectables Demand Share, 2019-2026
13. Middle East & Africa Sustained Release Injectables Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sustained Release Injectables Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sustained Release Injectables Market Size and Volume Forecast by Application
13.4.1. Diabetes
13.4.2. Leukemia
13.4.3. Acromegaly
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sustained Release Injectables Market Size and Volume Forecast by Type
13.7.1. Naltrexone
13.7.2. Exenatide
13.7.3. Estradiol
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sustained Release Injectables Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sustained Release Injectables Market: Market Share Analysis
14.2. Sustained Release Injectables Distributors and Customers
14.3. Sustained Release Injectables Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aurobindo
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Avadel
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Biomarin
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Camurus
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Critical Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Alkermes
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Amylin
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Ascendis Pharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Taiwan Liposome Company
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
